What will novel CAR-T cells look like in the future?

In a few years time the next generation CAR-T cell therapies are going to look and behave very…

March 9, 2023

A lysing kind of winter

Improving cell therapy performance with a multitude of innovative strategies

March 7, 2023

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023

Emerging biotechs and novel IO concepts to watch out for

10 early stage IO biotechs to watch out for

November 30, 2022

SITC Preview 2 – a look at novel and emerging IO targets

Five areas of early stage IO developments to watch out for

October 14, 2022

Up and coming cell therapy companies to watch out for

What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?

May 24, 2022


New CAR-T cell developments in solid tumours - hit or miss?

April 24, 2022

An inconvenient truth

Looking beyond the hype from a broader perspective

April 18, 2022

The paradox of immune cell populations and transcription factors

Can you have your immune cake and eat it?

March 23, 2022
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

TRIPLE highlights and lowlights in Developmental Therapeutics

The trials and tribulations of targeted agents in developmental therapeutics

October 25, 2020

Advent of a new era in advanced prostate cancer treatment

A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer

June 3, 2021

Dancing with proteins at the Masquerade

Who's going to the masquerade ball and how might they fare in the future?

June 1, 2021

Off the Beaten ASCO21 Track Part 1

Hidden early stage gems to watch out for at ASCO21

May 25, 2021

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021

The Future of Cell and Gene Therapies

13 ways in which CAR based or gene therapies can improve on current approaches to cell therapies

April 22, 2021

Novel approaches to cell therapies – Part 1

A look at switchable CAR-T cell therapies, plus CARs based on alternative immune cells.

April 19, 2021

Fifteen AACR21 On Demand Presentations To Watch

Noteworthy AACR21 on-demand presentations.

March 23, 2021

Highlights from Mini Oral Sessions at ESMO20

Commentary on Day 1 at ESMO20 and data presented in the mini oral sessions

September 19, 2020

ESMO20 Preview 3 Developmental Therapeutics – IO therapies

Five IO areas in early stage development to watch out for at ESMO20

September 15, 2020

Putting NK cells to work

Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...

July 7, 2020

Will a novel way to target IL–18 be a winner?

Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?

June 29, 2020

Engineering Immunity – what did we learn from ASGCT20?

There are some creative and innovative new CAR T cell therapy designs being developed - what are they and where will they be tested?

May 14, 2020

ASGCT20 Gems from the ePoster Hall

Review of 12 posters that caught our attention in the ePoster Hall at ASGCT20

May 14, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

Exploring the immunological links between lung cancer and Covid–19

Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?

March 31, 2020

Insights of the Decade

The December 17, 2010 issue of "Science" has the catchy of title of "Insights of the Decade", one of which is the ubiquitous role of inflammation in multiple chronic illnesses including cancer.

January 3, 2011

The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15

Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma

November 11, 2019

Waves and waves of T cells

What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy

June 27, 2019

Navigating new opportunities in the IL-2 space

How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?

June 26, 2019

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019

Alternative approaches to targeting cytokines

Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?

June 19, 2019

New developments in cytokines as immune modulators

New insights emerging from research on cytokines as an effective way to induce anti tumour immunity

January 31, 2019

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

November 13, 2018

An analysis of Nektar’s latest PIVOT data and pipeline update

Update on PIVOT-02 with nivolumab plus NKTR-214 in 1L metastatic melanoma

November 12, 2018

Learnings from IO combinations and where we’re headed

Lessons learned from recent failure and a look at where a few new developments might be coming from...

August 23, 2018

Armored CAR-T cell therapies and commercial threats from the East

On launched products, armored CARs and the potential threat from China

August 16, 2018

In a Prudential Light

Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.

June 19, 2018

The Potential for Cytokines in Cancer Immunotherapy

The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...

June 18, 2018

How should we interpret the NKTR–214 data presented at ASCO?

What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?

June 14, 2018

Stacking up evidence from IO clinical trials

A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18

May 3, 2018

Bench to bedside and back again

A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types

May 1, 2018

Targeting TGF-β and the tumour microenvironment

A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy

April 30, 2018

Targeting NK cells effectively in AML

A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies

March 14, 2018

Update on cytokines as novel cancer immunotherapy

A look at innate approaches to stimulating the immune system including IL-15 agonists

February 21, 2018

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017
National Harbor from Gaylord Hotel

SITC17 – Final Look at what to watch out for

Final SITC17 Preview and a look at key talks now that the abstracts are available.

November 8, 2017

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017

SITC 2016 Can Nektar Boost Checkpoint Performance

Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...

November 16, 2016